Landscape Capital Management L.L.C. Invests $4.17 Million in Boston Scientific Corporation $BSX

Landscape Capital Management L.L.C. acquired a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 97,691 shares of the medical equipment provider’s stock, valued at approximately $4,169,000.

A number of other large investors also recently modified their holdings of BSX. Renaissance Group LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth approximately $28,064,000. Perigon Wealth Management LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd boosted its stake in shares of Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after purchasing an additional 670,060 shares in the last quarter. PensionDanmark Pensionsforsikringsaktieselskab grew its holdings in shares of Boston Scientific by 9.9% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after purchasing an additional 28,961 shares during the last quarter. Finally, Meiji Yasuda America Inc bought a new position in shares of Boston Scientific during the 4th quarter valued at $4,708,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BSX. Raymond James Financial reissued an “outperform” rating and issued a $57.00 price target on shares of Boston Scientific in a research note on Thursday, July 30th. Mizuho reduced their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 15th. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a report on Friday, June 12th. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, Truist Financial dropped their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Michael F. Mahoney acquired 186,240 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 194,522 shares of company stock worth $9,385,210 in the last 90 days. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Up 2.1%

NYSE:BSX opened at $50.39 on Friday. The firm has a market capitalization of $73.03 billion, a P/E ratio of 20.40, a P/E/G ratio of 1.08 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The company has a fifty day moving average of $46.34 and a 200 day moving average of $57.86. Boston Scientific Corporation has a 52 week low of $42.20 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the firm earned $0.75 EPS. The company’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific announced that its board has authorized a stock repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.